目的 觀察益血生膠囊聯(lián)合人粒細胞集落刺激因子對婦科腫瘤化療后白細胞下降的臨床療效，并探討了其臨床使用安全性。方法 收集2013年4月-2015年8月周口市中醫(yī)院治療的婦科腫瘤化療后白細胞下降患者124例，使用數(shù)字法隨機分為對照組和觀察組，每組62例。對照組給予人粒細胞集落刺激因子，150 μg/d，皮下注射，1次/d，觀察組在對照組基礎上加用益血生膠囊，4粒/次，口服，3次/d，4周為1療程。比較兩組治療前后血細胞計數(shù)、Spitzer生存質量指數(shù)評分量表（Spitzer評分）和癌癥康復評價簡表（Cares-SF評分）以及治療期間不良反應發(fā)生率的差異。結果 兩組治療前白細胞、紅細胞和血小板計數(shù)均無顯著性差異，治療后兩組白細胞、紅細胞和血小板計數(shù)均出現(xiàn)顯著升高（P<0.05、0.01），但觀察組對白細胞、紅細胞和血小板的升高作用優(yōu)于對照組（P<0.05）。兩組治療前Spitzer和Cares-SF評分均無顯著性差異，治療后兩組Spitzer評分均出現(xiàn)顯著升高和Cares-SF評分均出現(xiàn)顯著減低（P<0.05、0.01），但觀察組對Spitzer評分的升高作用以及Cares-SF評分的減低作用優(yōu)于對照組（P<0.05）。觀察組感染發(fā)生率為22.6%（14/62）顯著低于對照組的38.7%（24/62）（P<0.05）。對照組人粒細胞集落刺激因子使用（17.24±3.52）支，顯著高于觀察組的（12.14±2.73）支（P<0.05）。觀察組臨床治療不良反應率為8.1%（5/62），顯著低于對照組的21.0%（13/62）（P<0.05）。結論 益血生膠囊聯(lián)合人粒細胞集落刺激因子可顯著升高婦科腫瘤化療后白細胞下降患者的血細胞，改善患者臨床癥狀，提高生活質量，臨床使用安全。

Objective To detect the clinical effect of Yixuesheng Capsule on white blood cell decline in gynecological tumor patients undergoing chemotherapy and its clinical efficacy. Methods A total of 124 gynecological tumor patients with white blood cell decline were enrolled in this study. Patients were randomly divided into control group (n=62) and observation group (n=62). The control group were given rhG-CSF treatment, and the observation group were treated with Yixuesheng Capsule and rhG-CSF. The blood cell count, Spitzer score, Cares-SF score, and adverse reaction were compared. Results There was no significant difference of white blood cell (WBC), red blood cell (RBC), and platelet counts. After treatment, the WBC, RBC, and platelet count were significantly increased in the two groups (P<0.05, 0.01). But the observation group was better than the control group (P<0.05) on the increase of WBC, RBC, and platelet. There was no significant difference of Spitzer score and Cares-SF score between the two groups before treatment. After treatment, Spitzer scores of the two groups were significantly increased and Cares-SF scores were significantly decreased (P<0.05, 0.01), but the observation group of Spitzer score increased and Cares-SF score decreased superior than those of the control group (P<0.05). The incidence of infection in observation group was 22.6% (14/62), which was significantly lower than that of 38.7% (24/62) in control group (P<0.05). The usage of rhG-CSF in control group was 17.24 ±3.52, which was significantly higher than that of 12.14 ±2.73 in observation group (P<0.05). The rate of adverse reaction was 8.1% (5/62) in observation group which was lower than that of 21.0% (13/62) in control group (P<0.05). Conclusion Yixuesheng Capsule can significantly increase the blood cells of gynecological tumor patients undergoing chemotherapy, improve the clinical symptoms and the quality of life, with significantly clinical safety.